TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01974544
Drug: General interventions for all groups: blood presure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
Study: NCT01974544
Drug: General interventions for all groups: dysilipidemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration \>4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (\>4.0 mmol/L).
Study: NCT03751111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
Study: NCT01389752
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04646759
Drug: Capecitabine combined with Pyrotinib
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
Study: NCT01319695
Drug: recombinant follicle stimulating hormone (FSH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm
Study: NCT00881400
Drug: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03072056
Drug: MIN-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01643135
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
Study: NCT01604265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
Study: NCT00455429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
Study: NCT00455429
Drug: JNJ-26113100 (50 mg) once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
Study: NCT03149081
Drug: Boswellia
Normalized name: boswellia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia is an extract from frankincense
Study: NCT00455429
Drug: JNJ-26113100 (100 mg) once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
Study: NCT00455429
Drug: JNJ-26113100 (100 mg) twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
Study: NCT00455429
Drug: JNJ-26113100 (250 mg) twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
Study: NCT04545060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
Study: NCT01832974
Drug: IL-13-PE
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-13-PE intravenous infusion
Study: NCT03341962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets manufactured to mimic IMU-838 tablets
Study: NCT00239863
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03869528
Drug: 5 sprays of 10% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 sprays of 10% lignocaine
Study: NCT03869528
Drug: 10 sprays of 10% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 sprays of 10% lignocaine
Study: NCT04082754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride, same volume and same duration as CSL311
Study: NCT01544946
Drug: placebo po
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile water
Study: NCT00800332
Drug: CYT003-QbG10
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT00800332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT01217814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT01880632
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
Study: NCT01217814
Drug: methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)
Study: NCT01217814
Drug: Folic/folinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.
Study: NCT00963937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Study: NCT02433730
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular injection
Study: NCT02433730
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular injection
Study: NCT02298829
Drug: Subjects Previously Treated with AA4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment to be administered - observational only
Study: NCT02970292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken as two tablets, once daily by mouth
Study: NCT00372437
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 as an oral dose three times per week.
Study: NCT03440359
Drug: Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe
Normalized name: Ovidrel 250 MCG per 0.5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: ovidrel 250 mcg given when leading follicle size is \> 17 mm in diameter
Study: NCT00910793
Drug: Inuvair
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
Study: NCT04041284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03464656
Drug: Fairhaven Pro for men
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)
Study: NCT02246166
Drug: Test tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
Study: NCT01827631
Drug: GSK1605786 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish Orange, size 0, hard gelatine capsules
Study: NCT01385735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 Tbl per day, 12 week (84 days) duration
Study: NCT03478111
Drug: CMAB008
Approvals — FDA: no, EMA: no, PMDA: no
Description: the study drug
Study: NCT02980224
Drug: OmegaD
Approvals — FDA: no, EMA: no, PMDA: no
Description: OmegaD Softgels
Study: NCT02980224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Softgels
Study: NCT02455401
Drug: High dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
Study: NCT02455401
Drug: Low dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
Study: NCT02455401
Drug: No remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: no remifentanil will be administrated
Study: NCT00189462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01233622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03769896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, corn starch, daily basis
Study: NCT01966666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mL 0.9% sodium chloride.
Study: NCT02320396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT03977207
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroid hormone supplement
Study: NCT03977207
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT02595723
Drug: Phenytoin 200 mg capsule
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
Study: NCT02595723
Drug: Phenytoin-matched Placebo capsule
Normalized name: phenytoin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
Study: NCT02535611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
Study: NCT03051360
Drug: PCSK9 Inhibitor [EPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive PCSK9 inhibitor by a biweekly injection
Study: NCT03051360
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Placebo by a biweekly injection
Study: NCT00000522
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01441531
Drug: Placebo pill given one hour before surgery
Normalized name: Vitafol-One Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill given
Study: NCT02986594
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01925209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Study: NCT00996944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
Study: NCT03594227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - oral administration
Study: NCT04622345
Drug: VSJ-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT04622345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT04803500
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single injection of simvastatin gel in the gap around immediately placed implant
Study: NCT04803500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
Study: NCT01964404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with no active ingredient
Study: NCT02881034
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04754035
Drug: Imbruvica Oral Product
Normalized name: Imbruvica Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imbruvica 140 mg
Study: NCT02510118
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
Study: NCT02510118
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
Study: NCT02194127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02510118
Drug: Placebo ChangTai Keli
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
Study: NCT02510118
Drug: ChangTai Keli
Normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
Study: NCT03059615
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
Study: NCT00367861
Drug: interruption of Glivec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: interruption of Glivec®
Study: NCT02606253
Drug: Chlorothiazide
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
Study: NCT01455688
Drug: early HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of HAART within 5 days of ICU admission
Study: NCT01455688
Drug: Late HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of HAART after ICU discharge
Study: NCT04243863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study: NCT03568890
Drug: Low dose aspirin -80 to 125 mg/day-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of treatment: 60 days
Study: NCT00464204
Drug: 0.9 % NaCl
Normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
Study: NCT00674050
Drug: Technosphere Insulin (TI) Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
Study: NCT00962832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as a sterile liquid solution.
Study: NCT02014636
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
Study: NCT00035282
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03253276
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01806363
Drug: Chlorthalidone 25mg
Normalized name: CHLORTHALIDONE 25MG TAB
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04296370
Drug: Physician's choice chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators will declare one of the following regimens:~Capecitabine Vinorelbine
Study: NCT01962571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03931460
Drug: Medical Abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Abortion
Study: NCT01154374
Drug: MEBO Wound Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application twice daily
Study: NCT02441283
Drug: ABT-493
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Study: NCT02076997
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.
Study: NCT02774382
Drug: Rectal bacteriotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Already incl. in arm description
Study: NCT02441283
Drug: ABT-530
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Study: NCT01325441
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01664728
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
Study: NCT00041392
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02348463
Drug: Clindamycin-2-phosphate
Normalized name: Acanya (benzoyl peroxide 2.5 % / clindamycin-2-phosphate 1.2 % ) Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: how many women will deliver before the 37th week of gestation
Study: NCT03506763
Drug: Diclofenac oral + Placebo Oral
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac oral + Placebo Oral
Study: NCT03506763
Drug: Diclofenac oral + scopolamina oral
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac oral + scopolamina oral
Study: NCT00988663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: will give placebo that looks like memantine
Study: NCT03957564
Drug: Neoadjuvant chemotherapy with PSOX regimen.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle.
Study: NCT04276428
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT01648582
Drug: Sulfonylureas
Normalized name: Sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Study: NCT00448591
Drug: Taxane-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT01871662
Drug: Legalon® SIL (Silibinin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silibinin 20 mg/Kg/day
Study: NCT00972673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator
Study: NCT00972673
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid
Study: NCT01844050
Drug: Chinese herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
Study: NCT01844050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229838
Drug: BIBB 1464 MS placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01959672
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01959672
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01160796
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x14-day course of treatment during 4 cycles
Study: NCT01160796
Drug: Lcr35®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x14-day course of treatment during 4 cycles
Study: NCT00589186
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03208244
Drug: Clinically prescribed direct acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment for 12 weeks